MX357447B - Tratamiento terapeutico. - Google Patents

Tratamiento terapeutico.

Info

Publication number
MX357447B
MX357447B MX2013011413A MX2013011413A MX357447B MX 357447 B MX357447 B MX 357447B MX 2013011413 A MX2013011413 A MX 2013011413A MX 2013011413 A MX2013011413 A MX 2013011413A MX 357447 B MX357447 B MX 357447B
Authority
MX
Mexico
Prior art keywords
taxane
compound
relates
treatment
therapeutic treatment
Prior art date
Application number
MX2013011413A
Other languages
English (en)
Other versions
MX2013011413A (es
Inventor
Robert Davies Barry
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2013011413A publication Critical patent/MX2013011413A/es
Publication of MX357447B publication Critical patent/MX357447B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a una combinación que comprende (S)-4-amino-N-(1-(4-clorofenil)-3-hidroxipropil)-1-(7H-pirrolo[2, 3-d]pirimidin-4-iI)piperidin-4-carboxamida, o una sal farmacéuticamente aceptable de lo mismo, en lo sucesivo en la presente "Compuesto (I)", y un taxano. Los taxanos incluyen fármacos contra el cáncer establecidos tales como docetaxel (TaxotereTM) y paclitaxel (TaxolTM). Tales combinaciones pueden ser útiles en el tratamiento o la profilaxis del cáncer. La invención también se refiere a una composición farmacéutica que comprende tal Compuesto (I) y un taxano. La invención se refiere además a un método de tratamiento que comprende la administración simultánea, secuencial o por separado del Compuesto (I) y un taxano a un animal de sangre caliente como un humano. La invención también se refiere a un kit que comprende el Compuesto (I) y un taxano, opcionalmente con instrucciones de uso.
MX2013011413A 2011-04-01 2012-04-02 Tratamiento terapeutico. MX357447B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470668P 2011-04-01 2011-04-01
PCT/GB2012/050736 WO2012131399A1 (en) 2011-04-01 2012-04-02 Therapeutic treatment

Publications (2)

Publication Number Publication Date
MX2013011413A MX2013011413A (es) 2014-05-21
MX357447B true MX357447B (es) 2018-07-10

Family

ID=45976963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011413A MX357447B (es) 2011-04-01 2012-04-02 Tratamiento terapeutico.

Country Status (26)

Country Link
US (2) US9402847B2 (es)
EP (2) EP3620159A1 (es)
JP (1) JP6080837B2 (es)
KR (1) KR101851820B1 (es)
CN (1) CN103442708B (es)
AU (1) AU2012235902B2 (es)
BR (1) BR112013025410A2 (es)
CA (1) CA2831848C (es)
CY (1) CY1122608T1 (es)
DK (1) DK2694056T3 (es)
EA (1) EA027506B1 (es)
ES (1) ES2761311T3 (es)
HR (1) HRP20191927T1 (es)
HU (1) HUE047357T2 (es)
IL (1) IL228589B (es)
LT (1) LT2694056T (es)
ME (1) ME03589B (es)
MX (1) MX357447B (es)
MY (1) MY169449A (es)
PL (1) PL2694056T3 (es)
PT (1) PT2694056T (es)
RS (1) RS59568B1 (es)
SG (1) SG193505A1 (es)
SI (1) SI2694056T1 (es)
WO (1) WO2012131399A1 (es)
ZA (1) ZA201308176B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2694056T (lt) * 2011-04-01 2019-12-10 Astrazeneca Ab Terapinis gydymas
CN105142629B (zh) * 2013-03-04 2018-11-23 阿斯利康(瑞典)有限公司 组合治疗
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (es) 1963-04-04 1900-01-01
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CN100462066C (zh) 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
US6187778B1 (en) 1997-08-05 2001-02-13 Pfizer Inc. 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
MXPA03001777A (es) 2000-08-31 2003-06-04 Hoffmann La Roche Derivados de quinazolina como antagonistas adrenergicos alfa-1.
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
BR0115847A (pt) 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020182204A1 (en) * 2001-03-23 2002-12-05 Marie-Christine Bissery Combination of a taxane and a cyclin-dependent kinase
EP1474425B9 (en) 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ME00055B (me) * 2002-05-17 2010-10-10 Aventis Pharma Sa Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
EP1522314B1 (en) 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
WO2004043380A2 (en) 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
MXPA05005983A (es) 2002-12-04 2005-08-18 Eisai Co Ltd Compuestos de anillo fusionado 1,3-dihidroimidazol.
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
CA2507893A1 (en) 2003-04-21 2004-11-04 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
EP1698375B1 (en) 2003-12-25 2014-04-02 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
EP1848719B1 (en) 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
EP2016077A2 (en) 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
WO2007125325A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
TWI453021B (zh) * 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑
LT2694056T (lt) * 2011-04-01 2019-12-10 Astrazeneca Ab Terapinis gydymas

Also Published As

Publication number Publication date
PL2694056T3 (pl) 2020-03-31
EP2694056B1 (en) 2019-10-16
EP3620159A1 (en) 2020-03-11
BR112013025410A2 (pt) 2016-12-20
CA2831848C (en) 2020-12-22
ZA201308176B (en) 2015-12-23
AU2012235902A1 (en) 2013-05-02
JP6080837B2 (ja) 2017-02-15
KR101851820B1 (ko) 2018-06-04
WO2012131399A1 (en) 2012-10-04
CA2831848A1 (en) 2012-10-04
US9402847B2 (en) 2016-08-02
LT2694056T (lt) 2019-12-10
DK2694056T3 (da) 2020-01-02
PT2694056T (pt) 2019-11-20
EA027506B1 (ru) 2017-08-31
SG193505A1 (en) 2013-10-30
IL228589B (en) 2019-09-26
ME03589B (me) 2020-07-20
CY1122608T1 (el) 2021-03-12
US20160317540A1 (en) 2016-11-03
CN103442708B (zh) 2016-11-09
NZ616410A (en) 2015-09-25
IL228589A0 (en) 2013-12-31
EP2694056A1 (en) 2014-02-12
MX2013011413A (es) 2014-05-21
KR20140022856A (ko) 2014-02-25
HRP20191927T1 (hr) 2020-01-10
AU2012235902B2 (en) 2015-08-27
EA201391327A1 (ru) 2014-03-31
CN103442708A (zh) 2013-12-11
ES2761311T3 (es) 2020-05-19
SI2694056T1 (sl) 2019-12-31
US20140121227A1 (en) 2014-05-01
HUE047357T2 (hu) 2020-04-28
JP2014509639A (ja) 2014-04-21
RS59568B1 (sr) 2019-12-31
MY169449A (en) 2019-04-11

Similar Documents

Publication Publication Date Title
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
NZ751418A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
EA201291310A1 (ru) Композиция ингибитора jak для местного применения
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
AR082691A1 (es) Terapia de combinacion, producto farmaceutico, kit y uso
AR082692A1 (es) Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit
CY1122608T1 (el) Θεραπευτικη αγωγη
AR085183A1 (es) Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
MX2015011588A (es) Tratamiento de combinacion.
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
MX2014001823A (es) Combinaciones de corroles y estatinas.
WO2014015137A3 (en) Compositions and methods for treating dysproliferative diseases
CA2855719C (en) Apoaequorin for reducing neuronal injury due to ischemia
EA201391076A1 (ru) Комбинации
UY33332A (es) Compuestos de triazol como inhibidores de ksp

Legal Events

Date Code Title Description
FG Grant or registration